Vita 34 International AG: Spanish partner Secuvita takes a share in VITA 34

Vita 34 International AG / Alliance

Release of a Corporate News, transmitted by DGAP - a company of EquityStory
The issuer / publisher is solely responsible for the content of this announcement.

New major shareholder with strategic interest – strong growth in Spain

Leipzig/Madrid, September 27, 2007 – The VITA 34 International AG (ISIN
DE000A0BL849), the parent company of the leading umbilical cord blood bank
within the German-speaking countries VITA 34, has a new major shareholder.
VITA 34’s Spanish sales and marketing partner, the Secuvita S.L., has
acquired a share of 3.02 percent in the VITA 34 International AG. In
addition, Dr. Hans Hansmann, one of the principal shareholders of the
Secuvita S.L., has privately taken a share of 3.02 percent in VITA 34
International AG.

The investment of Secuvita S.L. in VITA 34 is regarded as a strategic
interest. The Spanish partner has herewith begun to expand the very
successful business relationship also in view of capital. Spain is becoming
more and more the motor of growth for the VITA 34 AG. Within the first six
months of 2007, the number of storages in Spain reached about 600, which
doubles the storages of umbilical cord blood transplants that were actually
planned for the entire year 2007.

Wolfgang Haselwander, CEO of the Secuvita S.L., explains: 'Our investment
in VITA 34 cements our partnership with the leading umbilical cord blood
bank in Europe. This means for our Spanish customers that they have access
to stem cell storages on the basis of the strict quality regulations of the
German Drug Law and the GMP certification. In other words: top quality,
know-how and service along the entire value chain. 'At the same time,
Secuvita in that way makes sure of the option to develop and apply the
latest stem cell processing technology and know-how on the Spanish market –
in cooperation with VITA 34.'

Dr. Eberhard Lampeter, CEO of the VITA 34 International AG, declares: 'We
appreciate the investment of our partner Secuvita in our stock. It
emphasizes our good and successful co-operation as well as the quality of
our umbilical cord blood bank.'

About VITA 34:

VITA 34 is the leading private umbilical cord blood bank in the
German-speaking area, having a market share of about 66 percent. Stem cell
transplants from umbilical cord blood are completely unobjectionable from
the ethical point of view and suitable for the treatment of diseases and
the application for regenerative medicine purposes. And the entire range of
applications of stem cells from umbilical cord blood is not yet foreseeable
due to the rapid progress in research and medicine. VITA 34 focuses on the
manufacture of autologous, i.e. body’s own stem cell preparations. On an
international scale, the German market still has a considerable potential
for development in view of the umbilical cord blood storages conducted by
parents in total.

About Secuvita:

Secuvita, S.L. offers Spanish families the private stem cell processing and
storage based on an exclusive agreement with the VITA 34 AG. Secuvita is
thus the only Spanish company offering stem cell storages on the basis of
the German Drug Law and the GMP certification. Therewith, Spanish families
can enjoy high-quality stem cell products to make individual arrangements.
Since 1997, more than 43,000 stem cell preparations were processed at VITA
34 and a part of them was successfully applied in the treatment of

Press/Investor Relations:
Axel Mühlhaus
Dr. Sönke Knop
edicto GmbH
Zeisselstrasse 19
D-60318 Frankfurt
Phone.: +49 (069) 90550552
Fax: +49 (069) 90550577

27.09.2007  Financial News transmitted by DGAP
Language:     English
Issuer:       Vita 34 International AG
              Deutscher Platz 5a
              04103 Leipzig
Phone:        +49(0341)48792-40
Fax:          +49(0341)48792-39
ISIN:         DE000A0BL849
WKN:          A0BL84
Listed:       Geregelter Markt in Frankfurt (Prime Standard); Freiverkehr
              in Berlin, Düsseldorf, Hamburg, München, Stuttgart
End of News                                     DGAP News-Service